Table 3.
Linear regression analysis between 25(OH)D levels and participant characteristics
|
Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| β | CI | p | β | CI | p | |
| Age (years) |
−0. 32 |
(−1.15, 0.51) |
0.4 |
|
|
|
| BMI |
−0.15 |
(−0.96, 0.65) |
0.7 |
|
|
|
| Time since JIA onset (years) |
−0.52 |
(−1.74, 0.69) |
0.4 |
|
|
|
| JIA subtype |
|
|
|
|
|
|
| Oligoarthritis |
0 |
|
|
|
|
|
| Systemic-onset arthritis |
−0.92 |
(−8.81, 6.96) |
0.8 |
|
|
|
| Polyarticular forms |
−0.55 |
(−7.61, 6.50) |
0.8 |
|
|
|
| CHAQ |
−3.28 |
(−7.31, 0.75) |
0.1 |
|
|
|
| Patient global health (cm) |
−0.17 |
(−0.35, −0.004) |
0.04 |
−0.6 |
(−0.50, 0.38) |
0.7 |
| Tender joints |
−0.79 |
(−1.47, −0.10) |
0.02 |
−1.23 |
(−3.76, 1.30) |
0.3 |
| Swollen joints |
−0.67 |
(−1.78, 0.42) |
0.2 |
|
|
|
| ESR (mm/h) |
−0.14 |
(−0.28, 0.004) |
0.05 |
−0.21 |
(−0.66, 0.23) |
0.3 |
| DAS28 |
−3.87 |
(−7.67, −0.07) |
0.04 |
4.02 |
(−0.66, 0.23) |
0.6 |
| BASDAI |
−1.88 |
(−6.40, 2.62) |
0.3 |
|
|
|
| Medications used: |
|
|
|
|
|
|
| NSAID |
1.45 |
(−6.67, 9.57) |
0.7 |
|
|
|
| Corticosteroid |
1.08 |
(−6.04, 8.2) |
0.7 |
|
|
|
| Methotrexate |
−3.63 |
(−10.73, 3.46) |
0.3 |
|
|
|
| Sulfassalazine |
−0.04 |
(−9.91, 9.83) |
0.9 |
|
|
|
| Biologics | 1.56 | (−11.81, 14.94) | 0.81 | |||
CI: confidence interval at 95%; BMI: body mass index; DAS28: disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; BASDAI: Bath AS Disease Activity Index; NSAID: non-steroidal anti-inflammatory drugs; CHAQ: Childhood Health Assessment Questionnaire.